Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Neoadjuvant NALIRIFOX Plus AD-XRT for Pancreatic Cancer
NCT05851924Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2023
- Primary completion
- Sep 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NALIRIFOX in pancreatic ductal adenocarcinoma (PDAC), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2023; status: recruiting.
02
Drugs
NALIRIFOX
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05851924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851924.